{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:35:24Z","timestamp":1793298924927,"version":"4.5.0"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012990","name":"Universit\u00e0 degli Studi di Siena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012990","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psoriatic disease (PsD) is a chronic systemic inflammatory condition associated with significant cardiometabolic comorbidities, including obesity, type 2 diabetes mellitus (T2DM), and cardiovascular (CV) disease. These comorbidities are interlinked via shared immunopathogenic mechanisms, notably chronic low-grade inflammation driven by Th1\/Th17 cytokines such as TNF, IL-6, and IL-17. Obesity, in particular, exacerbates PsD severity and treatment resistance, underscoring the need for integrated therapeutic strategies. This scoping review investigates the biological rationale and evidence for the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in PsD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Originally developed for T2DM, GLP-1RAs have demonstrated efficacy in reducing weight and improving glycemic control and CV outcomes. Evidence also suggests immunomodulatory properties through modulation of key inflammatory pathways and immune cell activity. We examined studies addressing: (1) the impact of obesity, T2DM, and CV disease on PsD; (2) outcomes of GLP-1RAs in these comorbidities; and (3) their potential in related rheumatologic and dermatologic diseases. GLP-1RAs show promise in reducing PsD burden by improving metabolic parameters and reducing systemic inflammation. Early clinical and preclinical data suggest benefits also in rheumatoid arthritis, osteoarthritis, osteoporosis, psoriasis, and hidradenitis suppurativa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications<\/jats:title>\n                    <jats:p>GLP-1RAs represent a novel, multifaceted therapeutic option in PsD, targeting both metabolic and inflammatory components. Further clinical trials are warranted to define their role in comprehensive PsD management and validate their disease-modifying potential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00011-025-02140-2","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T01:54:51Z","timestamp":1763690091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review"],"prefix":"10.1007","volume":"74","author":[{"given":"Simona","family":"Buonanno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1401-8343","authenticated-orcid":false,"given":"Carla","family":"Gaggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Terribili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Gentileschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"2","key":"2140_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2021.101692","volume":"35","author":"P Karmacharya","year":"2021","unstructured":"Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: a literature review. Best Pract Res Clin Rheumatol. 2021;35(2):101692. https:\/\/doi.org\/10.1016\/j.berh.2021.101692.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2140_CR2","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s10067-019-04663-6","volume":"38","author":"L Costa","year":"2019","unstructured":"Costa L, Ramonda R, Ortolan A, Favero M, Foti R, Visalli E, et al. Psoriatic arthritis and obesity: the role of anti-IL-12\/IL-23 treatment. Clin Rheumatol. 2019;38:2355\u201362. https:\/\/doi.org\/10.1007\/s10067-019-04663-6.","journal-title":"Clin Rheumatol"},{"key":"2140_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.970371","author":"E Toussirot","year":"2022","unstructured":"Toussirot E, Gallais-S\u00e9r\u00e9zal I, Aubin F. The cardiometabolic conditions of psoriatic disease. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.970371.","journal-title":"Front Immunol"},{"issue":"1","key":"2140_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010058","volume":"19","author":"L Puig","year":"2017","unstructured":"Puig L. Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. Int J Mol Sci. 2017;19(1):58. https:\/\/doi.org\/10.3390\/ijms19010058.","journal-title":"Int J Mol Sci"},{"key":"2140_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X21998279","author":"P Karmacharya","year":"2021","unstructured":"Karmacharya P, Ogdie A, Eder L. Psoriatic arthritis and the association with cardiometabolic disease: a narrative review. Ther Adv Musculoskelet Dis. 2021. https:\/\/doi.org\/10.1177\/1759720X21998279.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2140_CR6","unstructured":"World Health Organization Western Pacific Region (2016) The Asia-Pacific perspective: redefining obesity and its treatment [Internet] Geneva: World Health Organization; 2000"},{"issue":"7","key":"2140_CR7","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/1756-185X.12444","volume":"19","author":"O Dikbas","year":"2016","unstructured":"Dikbas O, Tosun M, Bes C, Tonuk SB, Aksehirli OY, Soy M. Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity. Int J Rheum Dis. 2016;19(7):672\u20137. https:\/\/doi.org\/10.1111\/1756-185X.12444.","journal-title":"Int J Rheum Dis"},{"key":"2140_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00368","author":"\u00c3 Toussirot","year":"2014","unstructured":"Toussirot \u00c3, Aubin F, Dumoulin G. Relationships between adipose tissue and psoriasis, with or without arthritis. Front Immunol. 2014. https:\/\/doi.org\/10.3389\/fimmu.2014.00368.","journal-title":"Front Immunol"},{"key":"2140_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40744-020-00229-0","volume":"7","author":"E Lubrano","year":"2020","unstructured":"Lubrano E, Scriffignano S, Azuaga AB, Ramirez J, Ca\u00f1ete JD, Perrotta FM. Impact of comorbidities on disease activity, patient global assessment, and function in psoriatic arthritis: a cross-sectional study. Rheumatol Ther. 2020;7:825\u201336. https:\/\/doi.org\/10.1007\/s40744-020-00229-0.","journal-title":"Rheumatol Ther"},{"key":"2140_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195123","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Facciorusso A, Singh AG, VandeCasteele N, Zarrinpar A, Prokop LJ, et al. Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS ONE. 2018;13:e0195123. https:\/\/doi.org\/10.1371\/journal.pone.0195123.","journal-title":"PLoS ONE"},{"key":"2140_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1085799","author":"J-Y Wang","year":"2023","unstructured":"Wang J-Y, Wang Q-W, Yang X-Y, Yang W, Li D-R, Jin J-Y, et al. GLP\u22121 receptor agonists for the treatment of obesity: role as a promising approach. Front Endocrinol (Lausanne). 2023. https:\/\/doi.org\/10.3389\/fendo.2023.1085799.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"13","key":"2140_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310449","volume":"24","author":"M-S Popoviciu","year":"2023","unstructured":"Popoviciu M-S, P\u0103duraru L, Yahya G, Metwally K, Cavalu S. Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials. Int J Mol Sci. 2023;24(13):10449. https:\/\/doi.org\/10.3390\/ijms241310449.","journal-title":"Int J Mol Sci"},{"key":"2140_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.997578","author":"J Chen","year":"2022","unstructured":"Chen J, Mei A, Wei Y, Li C, Qian H, Min X, et al. GLP-1 receptor agonist as a modulator of innate immunity. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.997578.","journal-title":"Front Immunol"},{"key":"2140_CR14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","volume":"15","author":"LD Ferguson","year":"2019","unstructured":"Ferguson LD, Siebert S, McInnes IB, Sattar N. Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. Nat Rev Rheumatol. 2019;15:461\u201374. https:\/\/doi.org\/10.1038\/s41584-019-0256-0.","journal-title":"Nat Rev Rheumatol"},{"key":"2140_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","volume":"20","author":"W-H Boehncke","year":"2011","unstructured":"Boehncke W-H, Boehncke S, Tobin A-M, Kirby B. The \u2018psoriatic march\u2019: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20:303\u20137. https:\/\/doi.org\/10.1111\/j.1600-0625.2011.01261.x.","journal-title":"Exp Dermatol"},{"key":"2140_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","volume":"15","author":"JU Scher","year":"2019","unstructured":"Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15:153\u201366. https:\/\/doi.org\/10.1038\/s41584-019-0175-0.","journal-title":"Nat Rev Rheumatol"},{"key":"2140_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.12.1527","author":"MD Herron","year":"2005","unstructured":"Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005. https:\/\/doi.org\/10.1001\/archderm.141.12.1527.","journal-title":"Arch Dermatol"},{"key":"2140_CR18","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1365-2133.2008.08707.x","volume":"159","author":"JA Kaye","year":"2008","unstructured":"Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159:895\u2013902. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08707.x.","journal-title":"Br J Dermatol"},{"key":"2140_CR19","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","volume":"7","author":"A Kumthekar","year":"2020","unstructured":"Kumthekar A, Ogdie A. Obesity and psoriatic arthritis: a narrative review. Rheumatol Ther. 2020;7:447\u201356. https:\/\/doi.org\/10.1007\/s40744-020-00215-6.","journal-title":"Rheumatol Ther"},{"issue":"4","key":"2140_CR20","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1136\/annrheumdis-2011-200478","volume":"71","author":"ZR Ash","year":"2012","unstructured":"Ash ZR, Tinazzi I, Gallego CC, Kwok C, Wilson C, Goodfield M, et al. Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. Ann Rheum Dis. 2012;71(4):553\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200478.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2140_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/BOR.0000000000000254","volume":"28","author":"M Van Mechelen","year":"2016","unstructured":"Van Mechelen M, Lories RJ. Microtrauma. Curr Opin Rheumatol. 2016;28(2):176\u201380. https:\/\/doi.org\/10.1097\/BOR.0000000000000254.","journal-title":"Curr Opin Rheumatol"},{"key":"2140_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/rheumatology\/kes242","volume":"52","author":"A Russolillo","year":"2013","unstructured":"Russolillo A, Iervolino S, Peluso R, Lupoli R, Di Minno A, Pappone N, et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology. 2013;52:62\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/kes242.","journal-title":"Rheumatology"},{"issue":"5","key":"2140_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054901","volume":"24","author":"AB Azuaga","year":"2023","unstructured":"Azuaga AB, Ram\u00edrez J, Ca\u00f1ete JD. Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci. 2023;24(5):4901. https:\/\/doi.org\/10.3390\/ijms24054901.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2140_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.34","volume":"3","author":"P Gonz\u00e1lez-Muniesa","year":"2017","unstructured":"Gonz\u00e1lez-Muniesa P, M\u00e1rtinez-Gonz\u00e1lez M-A, Hu FB, Despr\u00e9s J-P, Matsuzawa Y, Loos RJF, et al. Obesity. Nat Rev Dis Primers. 2017;3(1):17034. https:\/\/doi.org\/10.1038\/nrdp.2017.34.","journal-title":"Nat Rev Dis Primers"},{"issue":"23","key":"2140_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314982","volume":"23","author":"TV Kirichenko","year":"2022","unstructured":"Kirichenko TV, Markina YV, Bogatyreva AI, Tolstik TV, Varaeva YR, Starodubova AV. The role of adipokines in inflammatory mechanisms of obesity. Int J Mol Sci. 2022;23(23):14982. https:\/\/doi.org\/10.3390\/ijms232314982.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2140_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01655-6","volume":"8","author":"J Guo","year":"2023","unstructured":"Guo J, Zhang H, Lin W, Lu L, Su J, Chen X. Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther. 2023;8(1):437. https:\/\/doi.org\/10.1038\/s41392-023-01655-6.","journal-title":"Signal Transduct Target Ther"},{"key":"2140_CR27","doi-asserted-by":"publisher","DOI":"10.4110\/in.2022.22.e13","author":"C-S Park","year":"2022","unstructured":"Park C-S, Shastri N. The role of T cells in obesity-associated inflammation and metabolic disease. Immune Netw. 2022. https:\/\/doi.org\/10.4110\/in.2022.22.e13.","journal-title":"Immune Netw"},{"key":"2140_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.941071","author":"M Kamata","year":"2022","unstructured":"Kamata M, Tada Y. Dendritic cells and macrophages in the pathogenesis of psoriasis. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.941071.","journal-title":"Front Immunol"},{"key":"2140_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/569751","volume":"2013","author":"A Mavropoulos","year":"2013","unstructured":"Mavropoulos A, Rigopoulou EI, Liaskos C, Bogdanos DP, Sakkas LI. The role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritis. Clin Dev Immunol. 2013;2013:1\u20138. https:\/\/doi.org\/10.1155\/2013\/569751.","journal-title":"Clin Dev Immunol"},{"key":"2140_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cytogfr.2010.10.005","volume":"21","author":"M Ahmed","year":"2010","unstructured":"Ahmed M, Gaffen SL. IL-17 in obesity and adipogenesis. Cytokine Growth Factor Rev. 2010;21:449\u201353. https:\/\/doi.org\/10.1016\/j.cytogfr.2010.10.005.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"2140_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4062\/biomolther.2020.054","volume":"29","author":"J Hwang","year":"2021","unstructured":"Hwang J, Yoo JA, Yoon H, Han T, Yoon J, An S, et al. The role of leptin in the association between obesity and psoriasis. Biomol Ther (Seoul). 2021;29(1):11\u201321. https:\/\/doi.org\/10.4062\/biomolther.2020.054.","journal-title":"Biomol Ther (Seoul)"},{"key":"2140_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/PTT.S122959","volume":"7","author":"I Kruglikov","year":"2017","unstructured":"Kruglikov I, Wollina U. Local effects of adipose tissue in psoriasis and psoriatic arthritis. Psoriasis Targets Ther. 2017;7:17\u201325. https:\/\/doi.org\/10.2147\/PTT.S122959.","journal-title":"Psoriasis Targets Ther"},{"key":"2140_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2024.1411218","author":"CJ Rendon","year":"2024","unstructured":"Rendon CJ, Sempere L, Lauver A, Watts SW, Contreras GA. Anatomical location, sex, and age modulate adipocyte progenitor populations in perivascular adipose tissues. Front Physiol. 2024. https:\/\/doi.org\/10.3389\/fphys.2024.1411218.","journal-title":"Front Physiol"},{"key":"2140_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4081\/ejh.2010.e48","volume":"54","author":"A Sbarbati","year":"2010","unstructured":"Sbarbati A, Accorsi D, Benati D, Marchetti L, Orsini G, Rigotti G, et al. Subcutaneous adipose tissue classification. Eur J Histochem. 2010;54:48. https:\/\/doi.org\/10.4081\/ejh.2010.e48.","journal-title":"Eur J Histochem"},{"key":"2140_CR35","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000442876","volume":"201","author":"V Macchi","year":"2016","unstructured":"Macchi V, Porzionato A, Sarasin G, Petrelli L, Guidolin D, Rossato M, et al. The infrapatellar adipose body: a histotopographic study. Cells Tissues Organs. 2016;201:220\u201331. https:\/\/doi.org\/10.1159\/000442876.","journal-title":"Cells Tissues Organs"},{"issue":"7","key":"2140_CR36","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1136\/annrheumdis-2012-202218","volume":"72","author":"MH Hoffmann","year":"2013","unstructured":"Hoffmann MH, Bruns H, B\u00e4ckdahl L, Nereg\u00e5rd P, Niederreiter B, Herrmann M, et al. The cathelicidins LL-37 and rCRAMP are associated with pathogenic events of arthritis in humans and rats. Ann Rheum Dis. 2013;72(7):1239\u201348. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202218.","journal-title":"Ann Rheum Dis"},{"key":"2140_CR37","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/nrrheum.2016.49","volume":"12","author":"E Neumann","year":"2016","unstructured":"Neumann E, Junker S, Schett G, Frommer K, M\u00fcller-Ladner U. Adipokines in bone disease. Nat Rev Rheumatol. 2016;12:296\u2013302. https:\/\/doi.org\/10.1038\/nrrheum.2016.49.","journal-title":"Nat Rev Rheumatol"},{"key":"2140_CR38","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.169748","author":"M Cescon","year":"2015","unstructured":"Cescon M, Gattazzo F, Chen P, Bonaldo P. Collagen VI at a glance. J Cell Sci. 2015. https:\/\/doi.org\/10.1242\/jcs.169748.","journal-title":"J Cell Sci"},{"key":"2140_CR39","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.2337\/db10-0585","volume":"59","author":"A Divoux","year":"2010","unstructured":"Divoux A, Tordjman J, Lacasa D, Veyrie N, Hugol D, Aissat A, et al. Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat mass loss. Diabetes. 2010;59:2817\u201325. https:\/\/doi.org\/10.2337\/db10-0585.","journal-title":"Diabetes"},{"key":"2140_CR40","doi-asserted-by":"publisher","first-page":"5707","DOI":"10.4049\/jimmunol.180.8.5707","volume":"180","author":"M Schnoor","year":"2008","unstructured":"Schnoor M, Cullen P, Lorkowski J, Stolle K, Robenek H, Troyer D, et al. Production of type VI collagen by human macrophages: a new dimension in macrophage functional heterogeneity. J Immunol. 2008;180:5707\u201319. https:\/\/doi.org\/10.4049\/jimmunol.180.8.5707.","journal-title":"J Immunol"},{"key":"2140_CR41","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1074\/jbc.M115.705160","volume":"291","author":"T Maa\u00df","year":"2016","unstructured":"Maa\u00df T, Bayley CP, M\u00f6rgelin M, Lettmann S, Bonaldo P, Paulsson M, et al. Heterogeneity of collagen VI microfibrils. J Biol Chem. 2016;291:5247\u201358. https:\/\/doi.org\/10.1074\/jbc.M115.705160.","journal-title":"J Biol Chem"},{"key":"2140_CR42","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1159\/000335239","volume":"4","author":"SM Abdillahi","year":"2012","unstructured":"Abdillahi SM, Balvanovi\u0107 S, Baumgarten M, M\u00f6rgelin M. Collagen VI encodes antimicrobial activity: novel innate host defense properties of the extracellular matrix. J Innate Immun. 2012;4:371\u20136. https:\/\/doi.org\/10.1159\/000335239.","journal-title":"J Innate Immun"},{"key":"2140_CR43","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1002\/oby.21565","volume":"24","author":"S Gesta","year":"2016","unstructured":"Gesta S, Guntur K, Majumdar ID, Akella S, Vishnudas VK, Sarangarajan R, et al. Reduced expression of collagen VI alpha 3 (COL6A3) confers resistance to inflammation-induced MCP1 expression in adipocytes. Obesity. 2016;24:1695\u2013703. https:\/\/doi.org\/10.1002\/oby.21565.","journal-title":"Obesity"},{"key":"2140_CR44","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1160\/TH16-02-0112","volume":"115","author":"Q Braster","year":"2016","unstructured":"Braster Q, Silvestre-Roig C, Hartwig H, Kusters P, Aarts S, den Toom M, et al. Cathelicidin regulates myeloid cell accumulation in adipose tissue and promotes insulin resistance during obesity. Thromb Haemost. 2016;115:1237\u20139. https:\/\/doi.org\/10.1160\/TH16-02-0112.","journal-title":"Thromb Haemost"},{"issue":"2","key":"2140_CR45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/acr.20363","volume":"63","author":"CC Mok","year":"2011","unstructured":"Mok CC, Ko GTC, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken). 2011;63(2):195\u2013202. https:\/\/doi.org\/10.1002\/acr.20363.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2140_CR46","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/biof.5520310310","volume":"31","author":"T Ezure","year":"2007","unstructured":"Ezure T, Amano S. Adiponectin and leptin up-regulate extracellular matrix production by dermal fibroblasts. BioFactors. 2007;31:229\u201336. https:\/\/doi.org\/10.1002\/biof.5520310310.","journal-title":"BioFactors"},{"issue":"3","key":"2140_CR47","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/art.24293","volume":"60","author":"LG Alexopoulos","year":"2009","unstructured":"Alexopoulos LG, Youn I, Bonaldo P, Guilak F. Developmental and osteoarthritic changes in Col6a1 \u2010knockout mice: biomechanics of type VI collagen in the cartilage pericellular matrix. Arthritis Rheum. 2009;60(3):771\u20139. https:\/\/doi.org\/10.1002\/art.24293.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2140_CR48","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1469-7580.2007.00791.x","volume":"211","author":"HM Shaw","year":"2007","unstructured":"Shaw HM, Santer RM, Watson AHD, Benjamin M. Adipose tissue at entheses: the innervation and cell composition of the retromalleolar fat pad associated with the rat Achilles tendon. J Anat. 2007;211(4):436\u201343. https:\/\/doi.org\/10.1111\/j.1469-7580.2007.00791.x.","journal-title":"J Anat"},{"issue":"5","key":"2140_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127811","volume":"10","author":"J Pingel","year":"2015","unstructured":"Pingel J, Petersen MCH, Fredberg U, Kj\u00e6r SG, Quistorff B, Langberg H, et al. Inflammatory and metabolic alterations of Kager\u2019s fat pad in chronic Achilles tendinopathy. PLoS ONE. 2015;10(5):e0127811. https:\/\/doi.org\/10.1371\/journal.pone.0127811.","journal-title":"PLoS ONE"},{"key":"2140_CR50","doi-asserted-by":"publisher","first-page":"72","DOI":"10.15557\/JoU.2015.0006","volume":"15","author":"I Sudo\u0142-Szopi\u0144ska","year":"2015","unstructured":"Sudo\u0142-Szopi\u0144ska I, Kwiatkowska B, Prochorec-Sobieszek M, Ma\u015bli\u0144ski W. Enthesopathies and enthesitis. Part 1. Etiopathogenesis. J Ultrason. 2015;15:72\u201384. https:\/\/doi.org\/10.15557\/JoU.2015.0006.","journal-title":"J Ultrason"},{"key":"2140_CR51","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X241271886","author":"JC Williams","year":"2024","unstructured":"Williams JC, Hum RM, Rogers K, Maglio C, Alam U, Zhao SS. Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy. Ther Adv Musculoskelet Dis. 2024. https:\/\/doi.org\/10.1177\/1759720X241271886.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2140_CR52","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.reumae.2019.06.003","volume":"17","author":"J Gratac\u00f3s","year":"2021","unstructured":"Gratac\u00f3s J, Gal\u00edndez E, Ot\u00f3n T. Is obesity a predictor for lack of response to treatment in psoriatic arthritis? A systematic review. Reumatolog\u00eda Cl\u00ednica (English Edition). 2021;17:268\u201378. https:\/\/doi.org\/10.1016\/j.reumae.2019.06.003.","journal-title":"Reumatolog\u00eda Cl\u00ednica (English Edition)"},{"key":"2140_CR53","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/jcph.491","volume":"55","author":"JR Wade","year":"2015","unstructured":"Wade JR, Parker G, Kosutic G, Feagen BG, Sandborn WJ, Laveille C, et al. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn\u2019s disease. J Clin Pharmacol. 2015;55:866\u201374. https:\/\/doi.org\/10.1002\/jcph.491.","journal-title":"J Clin Pharmacol"},{"key":"2140_CR54","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13075-019-1849-3","volume":"21","author":"B Hern\u00e1ndez-Breijo","year":"2019","unstructured":"Hern\u00e1ndez-Breijo B, Plasencia-Rodr\u00edguez C, Navarro-Comp\u00e1n V, Mart\u00ednez-Feito A, Jochems A, Kneepkens EL, et al. Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis. Arthritis Res Ther. 2019;21:66. https:\/\/doi.org\/10.1186\/s13075-019-1849-3.","journal-title":"Arthritis Res Ther"},{"key":"2140_CR55","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/jdv.13884","volume":"31","author":"NM Mostafa","year":"2017","unstructured":"Mostafa NM, Nader AM, Noertersheuser P, Okun M, Awni WM. Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31:490\u20137. https:\/\/doi.org\/10.1111\/jdv.13884.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"2140_CR56","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","volume":"73","author":"MND Di Minno","year":"2014","unstructured":"Di Minno MND, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor \u03b1 blockers. Ann Rheum Dis. 2014;73(6):1157\u201362. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202812.","journal-title":"Ann Rheum Dis"},{"key":"2140_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/580404","volume":"2013","author":"J Dreiher","year":"2013","unstructured":"Dreiher J, Freud T, Cohen AD. Psoriatic arthritis and diabetes: a population-based cross-sectional study. Dermatol Res Pract. 2013;2013:1\u20137. https:\/\/doi.org\/10.1155\/2013\/580404.","journal-title":"Dermatol Res Pract"},{"key":"2140_CR58","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3899\/jrheum.160861","volume":"44","author":"L Eder","year":"2017","unstructured":"Eder L, Chandran V, Cook R, Gladman DD. The risk of developing diabetes mellitus in patients with psoriatic arthritis: a cohort study. J Rheumatol. 2017;44:286\u201391. https:\/\/doi.org\/10.3899\/jrheum.160861.","journal-title":"J Rheumatol"},{"key":"2140_CR59","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10067-018-4042-1","volume":"37","author":"R Queiro","year":"2018","unstructured":"Queiro R, Lorenzo A, Pardo E, Brandy A, Coto P, Ballina J. Prevalence and type II diabetes-associated factors in psoriatic arthritis. Clin Rheumatol. 2018;37:1059\u201364. https:\/\/doi.org\/10.1007\/s10067-018-4042-1.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"2140_CR60","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/BOR.0b013e32831bc0c4","volume":"21","author":"TW Burner","year":"2009","unstructured":"Burner TW, Rosenthal AK. Diabetes and rheumatic diseases. Curr Opin Rheumatol. 2009;21(1):50\u20134. https:\/\/doi.org\/10.1097\/BOR.0b013e32831bc0c4.","journal-title":"Curr Opin Rheumatol"},{"key":"2140_CR61","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.biopha.2018.02.103","volume":"101","author":"A Abdel-Moneim","year":"2018","unstructured":"Abdel-Moneim A, Bakery HH, Allam G. The potential pathogenic role of IL-17\/Th17 cells in both type 1 and type 2 diabetes mellitus. Biomed Pharmacother. 2018;101:287\u201392. https:\/\/doi.org\/10.1016\/j.biopha.2018.02.103.","journal-title":"Biomed Pharmacother"},{"key":"2140_CR62","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1074\/jbc.M101521200","volume":"277","author":"V Aguirre","year":"2002","unstructured":"Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in Insulin Receptor Substrate-1 blocks interactions with the Insulin Receptor and inhibits Insulin Action. J Biol Chem. 2002;277:1531\u20137. https:\/\/doi.org\/10.1074\/jbc.M101521200.","journal-title":"J Biol Chem"},{"key":"2140_CR63","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40744-020-00206-7","volume":"7","author":"G Dal Bello","year":"2020","unstructured":"Dal Bello G, Gisondi P, Idolazzi L, Girolomoni G. Psoriatic arthritis and diabetes mellitus: a narrative review. Rheumatol Ther. 2020;7:271\u201385. https:\/\/doi.org\/10.1007\/s40744-020-00206-7.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"2140_CR64","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/acr.22926","volume":"69","author":"A Polachek","year":"2017","unstructured":"Polachek A, Touma Z, Anderson M, Eder L. Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta\u2010analysis of observational studies. Arthritis Care Res (Hoboken). 2017;69(1):67\u201374. https:\/\/doi.org\/10.1002\/acr.22926.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"2140_CR65","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1136\/ard.2008.094839","volume":"68","author":"DD Gladman","year":"2009","unstructured":"Gladman DD, Ang M, Su L, Tom BDM, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009;68(7):1131\u20135. https:\/\/doi.org\/10.1136\/ard.2008.094839.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2140_CR66","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1136\/annrheumdis-2015-207980","volume":"75","author":"L Eder","year":"2016","unstructured":"Eder L, Wu Y, Chandran V, Cook R, Gladman DD. Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Ann Rheum Dis. 2016;75(9):1680\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207980.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2140_CR67","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1136\/annrheumdis-2014-205267","volume":"74","author":"L Eder","year":"2015","unstructured":"Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman DD. Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. Ann Rheum Dis. 2015;74(10):1830\u20135. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205267.","journal-title":"Ann Rheum Dis"},{"key":"2140_CR68","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/j.1468-3083.2012.04706.x","volume":"27","author":"Y Chin","year":"2013","unstructured":"Chin Y, Yu H, Li W, Ko Y, Chen G, Wu C, et al. Arthritis as an important determinant for psoriatic patients to develop severe vascular events in Taiwan: a nation-wide study. J Eur Acad Dermatol Venereol. 2013;27:1262\u20138. https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04706.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"2140_CR69","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/acr.20627","volume":"63","author":"JA Husted","year":"2011","unstructured":"Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken). 2011;63(12):1729\u201335. https:\/\/doi.org\/10.1002\/acr.20627.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"2140_CR70","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","volume":"74","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326\u201332. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205675.","journal-title":"Ann Rheum Dis"},{"key":"2140_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.742713","author":"J Ram\u00edrez","year":"2021","unstructured":"Ram\u00edrez J, Azuaga-Pi\u00f1ango AB, Celis R, Ca\u00f1ete JD. Update on cardiovascular risk and obesity in psoriatic arthritis. Front Med. 2021. https:\/\/doi.org\/10.3389\/fmed.2021.742713.","journal-title":"Front Med"},{"issue":"2","key":"2140_CR72","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0014-5793(87)81430-8","volume":"211","author":"JJ Holst","year":"1987","unstructured":"Holst JJ, \u00d8rskov C, Vagn Nielsen O, Schwartz TW. Truncated glucagon\u2010like peptide I, an insulin\u2010releasing hormone from the distal gut. FEBS Lett. 1987;211(2):169\u201374. https:\/\/doi.org\/10.1016\/0014-5793(87)81430-8.","journal-title":"FEBS Lett"},{"key":"2140_CR73","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27:740\u201356. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001.","journal-title":"Cell Metab"},{"issue":"2","key":"2140_CR74","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","volume":"41","author":"AJ Ahmann","year":"2018","unstructured":"Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258\u201366. https:\/\/doi.org\/10.2337\/dc17-0417.","journal-title":"Diabetes Care"},{"key":"2140_CR75","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2337\/dc20-1473","volume":"44","author":"JP Frias","year":"2021","unstructured":"Frias JP, Bonora E, Nevarez Ruiz L, Li YG, Yu Z, Milicevic Z, et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021;44:765\u201373. https:\/\/doi.org\/10.2337\/dc20-1473.","journal-title":"Diabetes Care"},{"key":"2140_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.212283","volume":"4","author":"L Prasad-Reddy","year":"2015","unstructured":"Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:1\u201319. https:\/\/doi.org\/10.7573\/dic.212283.","journal-title":"Drugs Context"},{"issue":"5","key":"2140_CR77","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","volume":"45","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Ahmann A, Cariou B, Chow F, Davies MJ, J\u00f3dar E, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1\u20137 trials. Diabetes Metab. 2019;45(5):409\u201318. https:\/\/doi.org\/10.1016\/j.diabet.2018.12.001.","journal-title":"Diabetes Metab"},{"issue":"1","key":"2140_CR78","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7570\/jomes22067","volume":"32","author":"R Sinha","year":"2023","unstructured":"Sinha R, Papamargaritis D, Sargeant JA, Davies MJ. Efficacy and safety of Tirzepatide in type 2 diabetes and obesity management. J Obesity Metabol Syndr. 2023;32(1):25\u201345. https:\/\/doi.org\/10.7570\/jomes22067.","journal-title":"J Obesity Metabol Syndr"},{"key":"2140_CR79","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqaa093","author":"HJ Grill","year":"2020","unstructured":"Grill HJ. A role for GLP-1 in treating hyperphagia and obesity. Endocrinology. 2020. https:\/\/doi.org\/10.1210\/endocr\/bqaa093.","journal-title":"Endocrinology"},{"key":"2140_CR80","doi-asserted-by":"publisher","first-page":"d7771","DOI":"10.1136\/bmj.d7771","volume":"344","author":"T Vilsboll","year":"2012","unstructured":"Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771\u2013d7771. https:\/\/doi.org\/10.1136\/bmj.d7771.","journal-title":"BMJ"},{"issue":"2","key":"2140_CR81","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/1479164112441526","volume":"9","author":"D Mundil","year":"2012","unstructured":"Mundil D, Cameron-Vendrig A, Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res. 2012;9(2):95\u2013108. https:\/\/doi.org\/10.1177\/1479164112441526.","journal-title":"Diab Vasc Dis Res"},{"key":"2140_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156038","volume":"161","author":"Z Xie","year":"2024","unstructured":"Xie Z, Zheng G, Liang Z, Li M, Deng W, Cao W. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. Metabolism. 2024;161:156038. https:\/\/doi.org\/10.1016\/j.metabol.2024.156038.","journal-title":"Metabolism"},{"key":"2140_CR83","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892.","journal-title":"N Engl J Med"},{"key":"2140_CR84","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1742-1241.2010.02500.x","volume":"64","author":"WE Schmidt","year":"2010","unstructured":"Schmidt WE. Early clinical studies with liraglutide. Int J Clin Pract. 2010;64:12\u201320. https:\/\/doi.org\/10.1111\/j.1742-1241.2010.02500.x.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"2140_CR85","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, et al. Effect of weekly subcutaneous Semaglutide vs daily Liraglutide on body weight in adults with overweight or obesity without diabetes. JAMA. 2022;327(2):138. https:\/\/doi.org\/10.1001\/jama.2021.23619.","journal-title":"JAMA"},{"key":"2140_CR86","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083\u201391. https:\/\/doi.org\/10.1038\/s41591-022-02026-4.","journal-title":"Nat Med"},{"issue":"3","key":"2140_CR87","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","volume":"33","author":"AM Chao","year":"2023","unstructured":"Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023;33(3):159\u201366. https:\/\/doi.org\/10.1016\/j.tcm.2021.12.008.","journal-title":"Trends Cardiovasc Med"},{"key":"2140_CR88","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"key":"2140_CR89","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402:613\u201326. https:\/\/doi.org\/10.1016\/S0140-6736(23)01200-X.","journal-title":"Lancet"},{"key":"2140_CR90","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29:2909\u201318. https:\/\/doi.org\/10.1038\/s41591-023-02597-w.","journal-title":"Nat Med"},{"issue":"1","key":"2140_CR91","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin W-Y, et al. Continued treatment with Tirzepatide for maintenance of weight reduction in adults with obesity. JAMA. 2024;331(1):38. https:\/\/doi.org\/10.1001\/jama.2023.24945.","journal-title":"JAMA"},{"key":"2140_CR92","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2337\/dc09-1914","volume":"33","author":"JB Buse","year":"2010","unstructured":"Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010;33:1255\u201361. https:\/\/doi.org\/10.2337\/dc09-1914.","journal-title":"Diabetes Care"},{"key":"2140_CR93","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20:463\u201374. https:\/\/doi.org\/10.1038\/s41569-023-00849-3.","journal-title":"Nat Rev Cardiol"},{"key":"2140_CR94","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"12","key":"2140_CR95","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.amjcard.2018.02.030","volume":"121","author":"SP Marso","year":"2018","unstructured":"Marso SP, Nauck MA, Monk Fries T, Rasmussen S, Treppendahl MB, Buse JB. Myocardial infarction subtypes in patients with type 2 diabetes mellitus and the effect of Liraglutide therapy (from the LEADER Trial). Am J Cardiol. 2018;121(12):1467\u201370. https:\/\/doi.org\/10.1016\/j.amjcard.2018.02.030.","journal-title":"Am J Cardiol"},{"key":"2140_CR96","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"key":"2140_CR97","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"key":"2140_CR98","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.7150\/ijbs.59965","volume":"17","author":"X Ma","year":"2021","unstructured":"Ma X, Liu Z, Ilyas I, Little PJ, Kamato D, Sahebka A, et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021;17:2050\u201368. https:\/\/doi.org\/10.7150\/ijbs.59965.","journal-title":"Int J Biol Sci"},{"issue":"7","key":"2140_CR99","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/iub.2031","volume":"71","author":"Y Tao","year":"2019","unstructured":"Tao Y, Ge G, Wang Q, Wang W, Zhang W, Bai J, et al. Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast\u2010like synoviocytes. IUBMB Life. 2019;71(7):969\u201377. https:\/\/doi.org\/10.1002\/iub.2031.","journal-title":"IUBMB Life"},{"key":"2140_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.05.034","volume":"74","author":"W Zheng","year":"2019","unstructured":"Zheng W, Pan H, Wei L, Gao F, Lin X. Dulaglutide mitigates inflammatory response in fibroblast-like synoviocytes. Int Immunopharmacol. 2019;74:105649. https:\/\/doi.org\/10.1016\/j.intimp.2019.05.034.","journal-title":"Int Immunopharmacol"},{"key":"2140_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105732","volume":"75","author":"X Du","year":"2019","unstructured":"Du X, Zhang H, Zhang W, Wang Q, Wang W, Ge G, et al. The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes. Int Immunopharmacol. 2019;75:105732. https:\/\/doi.org\/10.1016\/j.intimp.2019.105732.","journal-title":"Int Immunopharmacol"},{"key":"2140_CR102","unstructured":"Sullivan C, Gaoatswe G, Gibney J, Healy ML, Doran M, Kane D, et al. 2013 Treatment with the glucagon-like peptide-1 analogue liraglutide is associated with amelioration of disease activity in a prospective cohort study of patients with inflammatory arthritis"},{"key":"2140_CR103","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.99.EP24","author":"V Gavazova","year":"2024","unstructured":"Gavazova V, Pashkunova S. New therapeutic opportunities shared by obesity, type 2 diabetes and rheumatoid arthritis. Endocr Abstr. 2024. https:\/\/doi.org\/10.1530\/endoabs.99.EP24.","journal-title":"Endocr Abstr"},{"key":"2140_CR104","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00223-023-01150-8","volume":"114","author":"J Herrou","year":"2023","unstructured":"Herrou J, Mabilleau G, Lecerf J-M, Thomas T, Biver E, Paccou J. Narrative review of effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity. Calcif Tissue Int. 2023;114:86\u201397. https:\/\/doi.org\/10.1007\/s00223-023-01150-8.","journal-title":"Calcif Tissue Int"},{"key":"2140_CR105","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1530\/JOE-17-0278","volume":"236","author":"G Mabilleau","year":"2018","unstructured":"Mabilleau G, Pereira M, Chenu C. Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists. J Endocrinol. 2018;236:R29-42. https:\/\/doi.org\/10.1530\/JOE-17-0278.","journal-title":"J Endocrinol"},{"key":"2140_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.697442","author":"B Xie","year":"2012","unstructured":"Xie B, Chen S, Xu Y, Han W, Hu R, Chen M, et al. The impact of glucagon-like peptide 1 receptor agonists on bone metabolism and its possible mechanisms in osteoporosis treatment. Front Pharmacol. 2012. https:\/\/doi.org\/10.3389\/fphar.2021.697442.","journal-title":"Front Pharmacol"},{"key":"2140_CR107","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1210\/en.2007-1292","volume":"149","author":"C Yamada","year":"2008","unstructured":"Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, et al. The murine Glucagon-Like Peptide-1 receptor is essential for control of bone resorption. Endocrinology. 2008;149:574\u20139. https:\/\/doi.org\/10.1210\/en.2007-1292.","journal-title":"Endocrinology"},{"key":"2140_CR108","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.lfs.2013.01.001","volume":"92","author":"J-Y Kim","year":"2013","unstructured":"Kim J-Y, Lee S-K, Jo K-J, Song D-Y, Lim D-M, Park K-Y, et al. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST\/sclerostin in osteocytes. Life Sci. 2013;92:533\u201340. https:\/\/doi.org\/10.1016\/j.lfs.2013.01.001.","journal-title":"Life Sci"},{"issue":"1-3","key":"2140_CR109","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.regpep.2009.06.010","volume":"159","author":"B Nuche-Berenguer","year":"2010","unstructured":"Nuche-Berenguer B, Moreno P, Portal-Nu\u00f1ez S, Dap\u00eda S, Esbrit P, Villanueva-Pe\u00f1acarrillo ML. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept. 2010;159(1\u20133):61\u20136. https:\/\/doi.org\/10.1016\/j.regpep.2009.06.010.","journal-title":"Regul Pept"},{"issue":"4","key":"2140_CR110","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/1753-0407.12282","volume":"7","author":"H Sun","year":"2015","unstructured":"Sun H, Lu N, Luo X, Zhao L, Liu J. Liraglutide, the glucagon\u2010like peptide\u20101 receptor agonist, has anabolic bone effects in diabetic Goto\u2010 Kakizaki rats \u5229\u62c9\u9c81\u80bd, \u4e00\u79cd\u80f0\u9ad8\u8840\u7cd6\u7d20\u6837\u80bd\u20101\u53d7\u4f53\u6fc0\u52a8\u5242, \u5728\u7cd6\u5c3f\u75c5Goto\u2010Kakizaki\u5927\u9f20\u4e2d\u5177\u6709\u9aa8\u5408\u6210\u4ee3\u8c22\u4f5c\u7528. J Diabetes. 2015;7(4):584\u20138. https:\/\/doi.org\/10.1111\/1753-0407.12282.","journal-title":"J Diabetes"},{"issue":"12","key":"2140_CR111","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1002\/jcp.25033","volume":"230","author":"SA Mansur","year":"2015","unstructured":"Mansur SA, Mieczkowska A, Bouvard B, Flatt PR, Chappard D, Irwin N, et al. Stable incretin mimetics counter rapid deterioration of bone quality in type 1 diabetes mellitus. J Cell Physiol. 2015;230(12):3009\u201318. https:\/\/doi.org\/10.1002\/jcp.25033.","journal-title":"J Cell Physiol"},{"issue":"4","key":"2140_CR112","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.stemcr.2016.03.010","volume":"6","author":"J Meng","year":"2016","unstructured":"Meng J, Ma X, Wang N, Jia M, Bi L, Wang Y, et al. Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through \u03b2-catenin. Stem Cell Reports. 2016;6(4):633. https:\/\/doi.org\/10.1016\/j.stemcr.2016.03.010.","journal-title":"Stem Cell Reports"},{"key":"2140_CR113","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1463-1326.2010.01355.x","volume":"13","author":"MC Bunck","year":"2011","unstructured":"Bunck MC, Eliasson B, Corn\u00e9r A, Heine RJ, Shaginian RM, Taskinen M-R, et al. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:374\u20137. https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01355.x.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2140_CR114","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00592-015-0792-2","volume":"52","author":"R Li","year":"2015","unstructured":"Li R, Xu W, Luo S, Xu H, Tong G, Zeng L, et al. Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes. Acta Diabetol. 2015;52(6):1083\u201391. https:\/\/doi.org\/10.1007\/s00592-015-0792-2.","journal-title":"Acta Diabetol"},{"key":"2140_CR115","doi-asserted-by":"publisher","first-page":"406","DOI":"10.4158\/EP15758.OR5","volume":"22","author":"MP Gilbert","year":"2016","unstructured":"Gilbert MP, Michel M, Holst JJ, Garber A, Baeres FMM, Thomsen H, et al. Comparison of the long-term effects of liraglutide and glimepiride monotherapy on bone mineral density in patients with type 2 diabetes. Endocr Pract. 2016;22:406\u201311. https:\/\/doi.org\/10.4158\/EP15758.OR5.","journal-title":"Endocr Pract"},{"key":"2140_CR116","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.neuropharm.2017.09.040","volume":"128","author":"Z Xie","year":"2018","unstructured":"Xie Z, Enkhjargal B, Wu L, Zhou K, Sun C, Hu X, et al. Exendin-4 attenuates neuronal death via GLP-1R\/PI3K\/Akt pathway in early brain injury after subarachnoid hemorrhage in rats. Neuropharmacology. 2018;128:142\u201351. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.09.040.","journal-title":"Neuropharmacology"},{"issue":"9","key":"2140_CR117","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s40618-019-01034-5","volume":"42","author":"L Yang","year":"2019","unstructured":"Yang L, Yang J, Pan T, Zhong X. Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis. J Endocrinol Invest. 2019;42(9):1125\u201331. https:\/\/doi.org\/10.1007\/s40618-019-01034-5.","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2140_CR118","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.yexcr.2017.09.018","volume":"360","author":"X Wu","year":"2017","unstructured":"Wu X, Li S, Xue P, Li Y. Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)\/protein kinase B (AKT), extracellular signal-related kinase (ERK)1\/2, and cAMP\/protein kinase A (PKA) signaling pathways involving \u03b2-catenin. Exp Cell Res. 2017;360(2):281\u201391. https:\/\/doi.org\/10.1016\/j.yexcr.2017.09.018.","journal-title":"Exp Cell Res"},{"key":"2140_CR119","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00411","author":"B Xie","year":"2019","unstructured":"Xie B, Wu J, Li Y, Wu X, Zeng Z, Zhou C, et al. Geniposide alleviates glucocorticoid-induced inhibition of osteogenic differentiation in MC3T3-E1 cells by ERK pathway. Front Pharmacol. 2019. https:\/\/doi.org\/10.3389\/fphar.2019.00411.","journal-title":"Front Pharmacol"},{"key":"2140_CR120","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00223-009-9220-3","volume":"84","author":"B Nuche-Berenguer","year":"2009","unstructured":"Nuche-Berenguer B, Moreno P, Esbrit P, Dap\u00eda S, Caeiro JR, Cancelas J, et al. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int. 2009;84:453\u201361. https:\/\/doi.org\/10.1007\/s00223-009-9220-3.","journal-title":"Calcif Tissue Int"},{"key":"2140_CR121","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/jbmr.1898","volume":"28","author":"X Ma","year":"2013","unstructured":"Ma X, Meng J, Jia M, Bi L, Zhou Y, Wang Y, et al. Exendin-4, a Glucagon-Like Peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. J Bone Miner Res. 2013;28:1641\u201352. https:\/\/doi.org\/10.1002\/jbmr.1898.","journal-title":"J Bone Miner Res"},{"key":"2140_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1586589","author":"M Chen","year":"2025","unstructured":"Chen M, Lyu Y, Zhao J, Han X, Huang T, Yang T, et al. Use of GLP-1 receptor agonist and risk of osteoporosis among patients with type 2 diabetes: a real-world study. Front Endocrinol (Lausanne). 2025. https:\/\/doi.org\/10.3389\/fendo.2025.1586589.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2140_CR123","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/phar.70005","volume":"45","author":"M Ryan","year":"2025","unstructured":"Ryan M, Megyeri S, Nuffer W, Trujillo JM. The potential role of GLP -1 receptor agonists in osteoarthritis. Pharmacother: J Human Pharmacol Drug Therapy. 2025;45:177\u201386. https:\/\/doi.org\/10.1002\/phar.70005.","journal-title":"Pharmacother: J Human Pharmacol Drug Therapy"},{"key":"2140_CR124","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21449","author":"T Chowdhury","year":"2022","unstructured":"Chowdhury T, Bellamkonda A, Gousy N, Deb Roy P. The association between diabetes mellitus and osteoarthritis: does diabetes mellitus play a role in the severity of pain in osteoarthritis? Cureus. 2022. https:\/\/doi.org\/10.7759\/cureus.21449.","journal-title":"Cureus"},{"issue":"7","key":"2140_CR125","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","volume":"30","author":"DH Ryan","year":"2024","unstructured":"Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30(7):2049\u201357. https:\/\/doi.org\/10.1038\/s41591-024-02996-7.","journal-title":"Nat Med"},{"key":"2140_CR126","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2147\/PPA.S419304","volume":"18","author":"TL Jensen","year":"2024","unstructured":"Jensen TL, Br\u00f8nden A, Karstoft K, Sonne D, Christensen M. The body weight reducing effects of tirzepatide in people with and without type 2 diabetes: a review on efficacy and adverse effects. Patient Prefer Adherence. 2024;18:373\u201382. https:\/\/doi.org\/10.2147\/PPA.S419304.","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"2140_CR127","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1007\/s12325-022-02153-x","volume":"39","author":"M Jensterle","year":"2022","unstructured":"Jensterle M, Rizzo M, Haluz\u00edk M, Jane\u017e A. Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: a narrative review. Adv Ther. 2022;39(6):2452\u201367. https:\/\/doi.org\/10.1007\/s12325-022-02153-x.","journal-title":"Adv Ther"},{"issue":"1","key":"2140_CR128","doi-asserted-by":"publisher","DOI":"10.1186\/s12950-019-0218-y","volume":"16","author":"Q Que","year":"2019","unstructured":"Que Q, Guo X, Zhan L, Chen S, Zhang Z, Ni X, et al. The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA\/CREB pathway in a rat model of knee osteoarthritis. J Inflamm. 2019;16(1):13. https:\/\/doi.org\/10.1186\/s12950-019-0218-y.","journal-title":"J Inflamm"},{"key":"2140_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2020.02.760","author":"F Berenbaum","year":"2020","unstructured":"Berenbaum F, Meurot C, Vieubled M. Protective effects of intra-articular formulated liraglutide in osteoarthritis: preclinical studies. Osteoarthritis Cartilage. 2020. https:\/\/doi.org\/10.1016\/j.joca.2020.02.760.","journal-title":"Osteoarthritis Cartilage"},{"key":"2140_CR130","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41419-017-0217-y","volume":"9","author":"J Chen","year":"2018","unstructured":"Chen J, Xie J-J, Shi K-S, Gu Y-T, Wu C-C, Xuan J, et al. Glucagon-like peptide-1 receptor regulates endoplasmic reticulum stress-induced apoptosis and the associated inflammatory response in chondrocytes and the progression of osteoarthritis in rat. Cell Death Dis. 2018;9:212. https:\/\/doi.org\/10.1038\/s41419-017-0217-y.","journal-title":"Cell Death Dis"},{"key":"2140_CR131","first-page":"4800","volume":"11","author":"J Mei","year":"2019","unstructured":"Mei J, Sun J, Wu J, Zheng X. Liraglutide suppresses TNF-\u03b1-induced degradation of extracellular matrix in human chondrocytes: a therapeutic implication in osteoarthritis. Am J Transl Res. 2019;11:4800\u20138.","journal-title":"Am J Transl Res"},{"issue":"2","key":"2140_CR132","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.bbrc.2012.07.086","volume":"425","author":"D Shiraishi","year":"2012","unstructured":"Shiraishi D, Fujiwara Y, Komohara Y, Mizuta H, Takeya M. Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. Biochem Biophys Res Commun. 2012;425(2):304\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2012.07.086.","journal-title":"Biochem Biophys Res Commun"},{"key":"2140_CR133","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2019.7347","author":"S Wan","year":"2019","unstructured":"Wan S, Sun H. Glucagon-like peptide-1 modulates RAW264.7 macrophage polarization by interfering with the JNK\/STAT3 signaling pathway. Exp Ther Med. 2019. https:\/\/doi.org\/10.3892\/etm.2019.7347.","journal-title":"Exp Ther Med"},{"key":"2140_CR134","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41598-022-05323-7","volume":"12","author":"C Meurot","year":"2022","unstructured":"Meurot C, Martin C, Sudre L, Breton J, Bougault C, Rattenbach R, et al. Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci Rep. 2022;12:1567. https:\/\/doi.org\/10.1038\/s41598-022-05323-7.","journal-title":"Sci Rep"},{"key":"2140_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2020.108968","volume":"322","author":"H Li","year":"2020","unstructured":"Li H, Chen J, Li B, Fang X. The protective effects of dulaglutide against advanced glycation end products (AGEs)-induced degradation of type II collagen and aggrecan in human SW1353 chondrocytes. Chem Biol Interact. 2020;322:108968. https:\/\/doi.org\/10.1016\/j.cbi.2020.108968.","journal-title":"Chem Biol Interact"},{"key":"2140_CR136","first-page":"2081","volume":"11","author":"C Tong","year":"2019","unstructured":"Tong C, Liang H, Liu X, Yuan B, Xue B, Tong Z, et al. The protective effects of exenatide against AGEs-induced articular matrix degradation in human primary chondrocytes. Am J Transl Res. 2019;11:2081\u20139.","journal-title":"Am J Transl Res"},{"key":"2140_CR137","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1523\/JNEUROSCI.4703-13.2014","volume":"34","author":"N Gong","year":"2014","unstructured":"Gong N, Xiao Q, Zhu B, Zhang C-Y, Wang Y-C, Fan H, et al. Activation of spinal Glucagon-Like Peptide-1 receptors specifically suppresses pain hypersensitivity. J Neurosci. 2014;34:5322\u201334. https:\/\/doi.org\/10.1523\/JNEUROSCI.4703-13.2014.","journal-title":"J Neurosci"},{"key":"2140_CR138","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/art.39488","volume":"68","author":"T Neogi","year":"2016","unstructured":"Neogi T, Guermazi A, Roemer F, Nevitt MC, Scholz J, Arendt-Nielsen L, et al. Association of joint inflammation with pain sensitization in knee osteoarthritis: the Multicenter Osteoarthritis Study. Arthritis Rheumatology. 2016;68:654\u201361. https:\/\/doi.org\/10.1002\/art.39488.","journal-title":"Arthritis Rheumatology"},{"key":"2140_CR139","unstructured":"Berenbaum F, Meurot C, Martin C, Breton J, Jacques C, Favret J, et al. (2022) Beneficial structural impact of liraglutide, a glp1 receptor agonist, in three inflammatory and post-traumatic OA animal models"},{"key":"2140_CR140","unstructured":"Meurot C, Martin M, Vieubled M, Breton J, Toillon I, Rattenbach R, et al. (2024) Beyond pain and inflammation: intra-articular liraglutide\u2019s comprehensive benefits on synovial health and cartilage in osteoarthritis compared to dexamethasone"},{"issue":"4","key":"2140_CR141","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00125-013-3145-0","volume":"57","author":"AE Hogan","year":"2014","unstructured":"Hogan AE, Gaoatswe G, Lynch L, Corrigan MA, Woods C, O\u2019Connell J, et al. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia. 2014;57(4):781\u20134. https:\/\/doi.org\/10.1007\/s00125-013-3145-0.","journal-title":"Diabetologia"},{"issue":"2","key":"2140_CR142","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/ajcn\/nqaa328","volume":"113","author":"H Gudbergsen","year":"2021","unstructured":"Gudbergsen H, Overgaard A, Henriksen M, W\u00e6hrens EE, Bliddal H, Christensen R, et al. Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. Am J Clin Nutr. 2021;113(2):314\u201323. https:\/\/doi.org\/10.1093\/ajcn\/nqaa328.","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"2140_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.ocarto.2022.100255","volume":"4","author":"C Bartholdy","year":"2022","unstructured":"Bartholdy C, Overgaard A, Gudbergsen H, Bliddal H, Kristensen LE, Henriksen M. Changes in physical activity during a one-year weight loss trial with liraglutide vs placebo in participants with knee osteoarthritis: secondary analyses of a randomised controlled trial. Osteoarthr Cartil Open. 2022;4(2):100255. https:\/\/doi.org\/10.1016\/j.ocarto.2022.100255.","journal-title":"Osteoarthr Cartil Open"},{"key":"2140_CR144","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12700","author":"N Jamal","year":"2025","unstructured":"Jamal N, Hollabaugh W, Scott L, Takkouche S. Unravelling the ties that bind: The intersection of obesity, osteoarthritis, and inflammatory pathways with emphasis on glucagon\u2010like peptide\u20101 agonists. Clin Obes. 2025. https:\/\/doi.org\/10.1111\/cob.12700.","journal-title":"Clin Obes"},{"issue":"9","key":"2140_CR145","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/ard-2023-223845","volume":"82","author":"H Zhu","year":"2023","unstructured":"Zhu H, Zhou L, Wang Q, Cai Q, Yang F, Jin H, et al. Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort. Ann Rheum Dis. 2023;82(9):1218\u201326. https:\/\/doi.org\/10.1136\/ard-2023-223845.","journal-title":"Ann Rheum Dis"},{"key":"2140_CR146","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","volume":"391","author":"H Bliddal","year":"2024","unstructured":"Bliddal H, Bays H, Czernichow S, Udd\u00e9n Hemmingsson J, Hjelmes\u00e6th J, Hoffmann Morville T, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024;391:1573\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2403664.","journal-title":"N Engl J Med"},{"issue":"1","key":"2140_CR147","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ad.2023.06.017","volume":"115","author":"E Vilarrasa","year":"2024","unstructured":"Vilarrasa E, Nicolau J, de la Cueva P, Goday A, Gallardo F, Martorell A, et al. Agonistas del receptor de GLP-1 para el tratamiento de la obesidad en pacientes con dermatosis inmunomediadas. Actas Dermosifiliogr. 2024;115(1):56\u201365. https:\/\/doi.org\/10.1016\/j.ad.2023.06.017.","journal-title":"Actas Dermosifiliogr"},{"issue":"3","key":"2140_CR148","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","volume":"33","author":"L Lin","year":"2022","unstructured":"Lin L, Xu X, Yu Y, Ye H, He X, Chen S, et al. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. J Dermatolog Treat. 2022;33(3):1428\u201334. https:\/\/doi.org\/10.1080\/09546634.2020.1826392.","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"2140_CR149","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.medcli.2023.05.021","volume":"161","author":"J Nicolau","year":"2023","unstructured":"Nicolau J, Nadal A, Sanch\u00eds P, Pujol A, Nadal C, Masmiquel L. Effects of liraglutide among patients living with psoriasis and obesity. Med Clin (Barc). 2023;161(7):293\u20136. https:\/\/doi.org\/10.1016\/j.medcli.2023.05.021.","journal-title":"Med Clin (Barc)"},{"issue":"11","key":"2140_CR150","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1007\/s00125-011-2232-3","volume":"54","author":"AE Hogan","year":"2011","unstructured":"Hogan AE, Tobin AM, Ahern T, Corrigan MA, Gaoatswe G, Jackson R, et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia. 2011;54(11):2745\u201354. https:\/\/doi.org\/10.1007\/s00125-011-2232-3.","journal-title":"Diabetologia"},{"issue":"11","key":"2140_CR151","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/j.1468-3083.2012.04609.x","volume":"27","author":"T Ahern","year":"2013","unstructured":"Ahern T, Tobin A-M, Corrigan M, Hogan A, Sweeney C, Kirby B, et al. Glucagon\u2010like peptide\u20101 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013;27(11):1440\u20133. https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04609.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2140_CR152","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/bjd.12886","volume":"171","author":"M Buysschaert","year":"2014","unstructured":"Buysschaert M, Baeck M, Preumont V, Marot L, Hendrickx E, Van Belle A, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: a prospective case-series study. Br J Dermatol. 2014;171(1):155\u201361. https:\/\/doi.org\/10.1111\/bjd.12886.","journal-title":"Br J Dermatol"},{"key":"2140_CR153","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-21-0007","author":"G Costanzo","year":"2021","unstructured":"Costanzo G, Curatolo S, Bus\u00e0 B, Belfiore A, Gullo D. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case Rep. 2021. https:\/\/doi.org\/10.1530\/EDM-21-0007.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"1","key":"2140_CR154","doi-asserted-by":"publisher","DOI":"10.3390\/biom15010046","volume":"15","author":"J Petkovi\u0107-Dabi\u0107","year":"2025","unstructured":"Petkovi\u0107-Dabi\u0107 J, Bini\u0107 I, Cari\u0107 B, Bo\u017ei\u0107 L, Umi\u010devi\u0107-\u0160ipka S, Bednar\u010duk N, et al. Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial. Biomolecules. 2025;15(1):46. https:\/\/doi.org\/10.3390\/biom15010046.","journal-title":"Biomolecules"},{"key":"2140_CR155","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/jdv.12629","volume":"29","author":"A Faurschou","year":"2015","unstructured":"Faurschou A, Gyldenl\u00f8ve M, Rohde U, Thyssen JP, Zachariae C, Skov L, et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients \u2013 a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol. 2015;29:555\u20139. https:\/\/doi.org\/10.1111\/jdv.12629.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2140_CR156","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.diabres.2019.03.002","volume":"150","author":"X Xu","year":"2019","unstructured":"Xu X, Lin L, Chen P, Yu Y, Chen S, Chen X, et al. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study. Diabetes Res Clin Pract. 2019;150:167\u201373. https:\/\/doi.org\/10.1016\/j.diabres.2019.03.002.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"2140_CR157","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","volume":"82","author":"SR Goldburg","year":"2020","unstructured":"Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa. J Am Acad Dermatol. 2020;82(5):1045\u201358. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.090.","journal-title":"J Am Acad Dermatol"},{"key":"2140_CR158","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.3390\/jcm13216292","volume":"13","author":"PK Krajewski","year":"2024","unstructured":"Krajewski PK, Z\u0142otowska A, Szepietowski JC. The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects. J Clin Med. 2024;13:6292. https:\/\/doi.org\/10.3390\/jcm13216292.","journal-title":"J Clin Med"},{"key":"2140_CR159","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.medcli.2023.11.007","volume":"162","author":"J Nicolau","year":"2024","unstructured":"Nicolau J, Nadal A, Sanch\u00eds P, Pujol A, Masmiquel L, Nadal C. Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa. Med Clin (Barc). 2024;162:118\u201322. https:\/\/doi.org\/10.1016\/j.medcli.2023.11.007.","journal-title":"Med Clin (Barc)"},{"key":"2140_CR160","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/bjd\/ljae216","volume":"191","author":"D Lyons","year":"2024","unstructured":"Lyons D, Louly Nathan A, Pender E, Murray G, Smith C, Kirby B, et al. Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life. Br J Dermatol. 2024;191:631\u20133. https:\/\/doi.org\/10.1093\/bjd\/ljae216.","journal-title":"Br J Dermatol"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-025-02140-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-025-02140-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-025-02140-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T16:54:38Z","timestamp":1767200078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-025-02140-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":160,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2140"],"URL":"https:\/\/doi.org\/10.1007\/s00011-025-02140-2","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human participants and\/or animals"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"167"}}